About: Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus
Creator	Hohdatsu, Tsutomu Takano, Tomomi Chueh, Ling-Ling Chen, Hui-Wen Chang, Wei-Shan Chen, You-Ting Fang, Zih-Syun Tsai, Hsiao-Han Wang, Wen-Lin Hu, Che-Ming
Source	Medline; PMC
abstract	Feline infectious peritonitis (FIP), caused by a mutated feline coronavirus, is one of the most serious and fatal viral diseases in cats. The disease remains incurable, and there is no effective vaccine available. In light of the pathogenic mechanism of feline coronavirus that relies on endosomal acidification for cytoplasmic entry, a novel vacuolar ATPase blocker, diphyllin, and its nanoformulation are herein investigated for their antiviral activity against the type II feline infectious peritonitis virus (FIPV). Experimental results show that diphyllin dose-dependently inhibits endosomal acidification in fcwf-4 cells, alters the cellular susceptibility to FIPV, and inhibits the downstream virus replication. In addition, diphyllin delivered by polymeric nanoparticles consisting of poly(ethylene glycol)-block-poly(lactide-co-glycolide) (PEG-PLGA) further demonstrates an improved safety profile and enhanced inhibitory activity against FIPV. In an in vitro model of antibody-dependent enhancement of FIPV infection, diphyllin nanoparticles showed a prominent antiviral effect against the feline coronavirus. In addition, the diphyllin nanoparticles were well tolerated in mice following high-dose intravenous administration. This study highlights the therapeutic potential of diphyllin and its nanoformulation for the treatment of FIP.
has issue date	2017-10-12(xsd:dateTime)
bibo:doi	10.1038/s41598-017-13316-0
bibo:pmid	29026122
has license	cc-by
sha1sum (hex)	467ab436fea0423f0621af047cd6e5c6dae5260e
schema:url	https://doi.org/10.1038/s41598-017-13316-0
resource representing a document's title	Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus
has PubMed Central identifier	PMC5638965
has PubMed identifier	29026122
schema:publication	Sci Rep
resource representing a document's body	covid:467ab436fea0423f0621af047cd6e5c6dae5260e#body_text
is schema:about of	named entity 'cells' named entity 'pathogenic' named entity 'intravenous administration' named entity 'TARGETED' named entity 'ANTIVIRAL ACTIVITY' named entity 'OPEN' named entity 'INHIBITORY ACTIVITY' named entity 'EFFECT' named entity 'NOVEL' named entity 'INTRAVENOUS ADMINISTRATION' named entity 'ANTIVIRAL ACTIVITY' named entity 'ENHANCED' named entity 'SAFETY' named entity 'INFECTION' named entity 'EXPERIMENTAL RESULTS' named entity 'STUDY' named entity 'DIPHYLLIN' named entity 'ANTIVIRAL' named entity 'ACIDIFICATION' named entity 'POLYMERIC' named entity 'HIGH-DOSE' named entity 'MICE' named entity 'DELIVERED' named entity 'INVESTIGATED' named entity 'CELLS' named entity 'BLOCK' named entity 'FOLLOWING' named entity 'VACUOLAR ATPASE' named entity 'DOWNSTREAM' named entity 'ANTIBODY-DEPENDENT ENHANCEMENT' named entity 'LIGHT' named entity 'PLGA' named entity 'CYTOPLASMIC' named entity 'THERAPEUTIC' named entity 'ITS' named entity 'GLYCOL' named entity 'EXHIBITS' named entity 'HOST' named entity 'FELINE INFECTIOUS PERITONITIS VIRUS' named entity 'MECHANISM' named entity 'DOSE' named entity 'SUSCEPTIBILITY' named entity 'PROMINENT' named entity 'NANOPARTICLES' named entity 'POLY' named entity 'VIRUS REPLICATION' named entity 'ENTRY' named entity 'THEIR' named entity 'MODEL OF' named entity 'ADDITION' named entity 'FCWF-4' named entity 'PROFILE' named entity 'FELINE CORONAVIRUS' named entity 'TREATMENT' named entity 'FELINE CORONAVIRUS' named entity 'FIP' named entity 'IMPROVED' named entity 'POTENTIAL' named entity 'IN VITRO MODEL' named entity 'PATHOGENIC' named entity 'VACUOLAR ATPASE' named entity 'CELLULAR' named entity 'TYPE II' covid:arg/467ab436fea0423f0621af047cd6e5c6dae5260e named entity 'feline coronavirus' named entity 'inhibits' named entity 'prominent' named entity 'inhibitory' named entity 'nanoparticles' named entity 'tolerated' named entity 'acidification' named entity 'FIP'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software